表紙
市場調查報告書

鼻子息肉:開發中產品分析

Nasal Polyps - Pipeline Review, H2 2019

出版商 Global Markets Direct 商品編碼 465222
出版日期 內容資訊 英文 102 Pages
訂單完成後即時交付
價格
Back to Top
鼻子息肉:開發中產品分析 Nasal Polyps - Pipeline Review, H2 2019
出版日期: 2019年11月25日內容資訊: 英文 102 Pages
簡介

鼻息肉(NP)是鼻子或鼻竇內的非癌性腫瘤。症狀包括流鼻涕,打鼾,瘙癢,持續性鼻塞,臉痛,味覺喪失。危險因素包括哮喘,囊性纖維化,Churg-Strauss症候群(過敏性肉芽腫性血管炎),過敏性真菌性鼻竇炎等。治療包括使用治療過敏用的皮質類固醇及抗組織胺藥物,或治療慢性/復發性感染疾病用的抗生素。

本報告提供鼻子息肉的治療藥開發平台現狀及最新更新的各開發階段比較分析,提供您涵括最新的新聞和發表之企業和研究機關開發中治療藥,治療藥評估,後期階段及中止的計劃等相關資訊。

簡介

  • 調查範圍

鼻子息肉;概要

治療藥的開發

  • 開發中產品;概要
  • 各企業的產品
  • 企業開發中的產品

治療藥的評估

  • 標的別
  • 各作用機制
  • 各給藥途徑
  • 各分子類型

開發治療藥的企業

  • Allakos Inc
  • Cumberland Pharmaceuticals Inc
  • F. Hoffmann-La Roche Ltd
  • OptiNose US Inc
  • Regeneron Pharmaceuticals Inc

藥物簡介

  • AK-001
  • dupilumab
  • fluticasone propionate
  • ifetroban sodium
  • omalizumab

暫停中的計劃

產品開發的里程碑

  • 主要消息和新聞稿

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC11561IDB

Summary:

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides an overview of the Nasal Polyps (Ear Nose Throat Disorders) pipeline landscape.

Nasal polyps (Nasal polyposis) is an inflammatory condition develops in the nasal lining of nose. They are non-cancerous growths. Signs and symptoms include runny nose, postnasal drip, headache, snoring and loss of sense of taste. Risk factors include asthma, aspirin sensitivity, cystic fibrosis, Churg-strauss syndrome and allergic fungal sinusitis. Treatment includes steroid medications.

Report Highlights:

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Nasal Polyps - Pipeline Review, H2 2019, provides comprehensive information on the therapeutics under development for Nasal Polyps (Ear Nose Throat Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Nasal Polyps (Ear Nose Throat Disorders) pipeline guide also reviews of key players involved in therapeutic development for Nasal Polyps (Nasal Polyposis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II and Phase I stages are 1, 4, 3 and 2 respectively.

Nasal Polyps (Ear Nose Throat Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Nasal Polyps (Ear Nose Throat Disorders).
  • The pipeline guide reviews pipeline therapeutics for Nasal Polyps (Ear Nose Throat Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Nasal Polyps (Ear Nose Throat Disorders) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Nasal Polyps (Ear Nose Throat Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Nasal Polyps (Ear Nose Throat Disorders)

Reasons to buy:

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Nasal Polyps (Ear Nose Throat Disorders).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Nasal Polyps (Ear Nose Throat Disorders) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

  • List of Tables
  • List of Figures
  • Introduction
    • Global Markets Direct Report Coverage
  • Nasal Polyps (Nasal Polyposis) - Overview
  • Nasal Polyps (Nasal Polyposis) - Therapeutics Development
    • Pipeline Overview
    • Pipeline by Companies
    • Products under Development by Companies
  • Nasal Polyps (Nasal Polyposis) - Therapeutics Assessment
    • Assessment by Target
    • Assessment by Mechanism of Action
    • Assessment by Route of Administration
    • Assessment by Molecule Type
  • Nasal Polyps (Nasal Polyposis) - Companies Involved in Therapeutics Development
    • AnaptysBio Inc
    • F. Hoffmann-La Roche Ltd
    • GlaxoSmithKline Plc
    • Idorsia Pharmaceutical Ltd
    • Kyowa Kirin Co Ltd
    • Novartis AG
    • OptiNose US Inc
    • Pfizer Inc
    • Regeneron Pharmaceuticals Inc
    • Suzhou Connect Biopharmaceuticals Ltd
  • Nasal Polyps (Nasal Polyposis) - Drug Profiles
    • ACT-774312 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • benralizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • CBP-201 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • dupilumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • etokimab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fevipiprant - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • fluticasone propionate - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • mepolizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • omalizumab - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
    • PF-06817024 - Drug Profile
      • Product Description
      • Mechanism Of Action
      • R&D Progress
  • Nasal Polyps (Nasal Polyposis) - Dormant Projects
  • Nasal Polyps (Nasal Polyposis) - Discontinued Products
  • Nasal Polyps (Nasal Polyposis) - Product Development Milestones
    • Featured News & Press Releases
      • Oct 30, 2019: EC approves Dupixent's indication in chronic rhinosinusitis
      • Sep 20, 2019: Sanofi : CHMP recommends approval of Dupixent (dupilumab) for severe chronic rhinosinusitis with nasal polyposis
      • Sep 20, 2019: The Lancet publishes results from two positive phase 3 trials of Dupixent (dupilumab) in severe chronic Rhinosinusitis with Nasal Polyps
      • Sep 12, 2019: Optinose announces $150 million debt financing from Pharmakon
      • Jun 27, 2019: FDA approves Regeneron's antibody Dupixent for nasal polyposis
      • Jun 26, 2019: FDA approves first treatment for chronic rhinosinusitis with nasal polyps
      • Jun 03, 2019: Xolair (Omalizumab) significantly reduced nasal polyps and congestion symptoms in adults with chronic rhinosinusitis with nasal polyps in two phase III studies
      • May 07, 2019: Dupixent Filed for Sinusitis in Japan: Sanofi
      • Mar 11, 2019: FDA grants priority review for Sanofi's Dupixent to treat rhinosinusitis
      • Feb 19, 2019: Optinose announces issuance of four additional U.S. patents covering XHANCE
      • Feb 15, 2019: Optinose to highlight data at the 2019 AAAAI Annual Meeting in San Francisco
      • Dec 10, 2018: Optinose announces first patient enrolled in clinical trial of XHANCE for Chronic Sinusitis
      • Oct 18, 2018: Sanofi's Dupixent meets Phase III trial endpoints for rhinosinusitis
      • Oct 03, 2018: Optinose to highlight data at two upcoming scientific meetings
      • Aug 30, 2018: European Commission approves Nucala (mepolizumab) for the treatment of children with severe asthma
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Table 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019
  • Table 2: Number of Products under Development by Companies, H2 2019
  • Table 3: Products under Development by Companies, H2 2019
  • Table 4: Number of Products by Stage and Target, H2 2019
  • Table 5: Number of Products by Stage and Mechanism of Action, H2 2019
  • Table 6: Number of Products by Stage and Route of Administration, H2 2019
  • Table 7: Number of Products by Stage and Molecule Type, H2 2019
  • Table 8: Nasal Polyps (Nasal Polyposis) - Pipeline by AnaptysBio Inc, H2 2019
  • Table 9: Nasal Polyps (Nasal Polyposis) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
  • Table 10: Nasal Polyps (Nasal Polyposis) - Pipeline by GlaxoSmithKline Plc, H2 2019
  • Table 11: Nasal Polyps (Nasal Polyposis) - Pipeline by Idorsia Pharmaceutical Ltd, H2 2019
  • Table 12: Nasal Polyps (Nasal Polyposis) - Pipeline by Kyowa Kirin Co Ltd, H2 2019
  • Table 13: Nasal Polyps (Nasal Polyposis) - Pipeline by Novartis AG, H2 2019
  • Table 14: Nasal Polyps (Nasal Polyposis) - Pipeline by OptiNose US Inc, H2 2019
  • Table 15: Nasal Polyps (Nasal Polyposis) - Pipeline by Pfizer Inc, H2 2019
  • Table 16: Nasal Polyps (Nasal Polyposis) - Pipeline by Regeneron Pharmaceuticals Inc, H2 2019
  • Table 17: Nasal Polyps (Nasal Polyposis) - Pipeline by Suzhou Connect Biopharmaceuticals Ltd, H2 2019
  • Table 18: Nasal Polyps (Nasal Polyposis) - Dormant Projects, H2 2019
  • Table 19: Nasal Polyps (Nasal Polyposis) - Discontinued Products, H2 2019

List of Figures

  • Figure 1: Number of Products under Development for Nasal Polyps (Nasal Polyposis), H2 2019
  • Figure 2: Number of Products under Development by Companies, H2 2019
  • Figure 3: Number of Products by Targets, H2 2019
  • Figure 4: Number of Products by Stage and Targets, H2 2019
  • Figure 5: Number of Products by Mechanism of Actions, H2 2019
  • Figure 6: Number of Products by Stage and Mechanism of Actions, H2 2019
  • Figure 7: Number of Products by Routes of Administration, H2 2019
  • Figure 8: Number of Products by Stage and Routes of Administration, H2 2019
  • Figure 9: Number of Products by Molecule Types, H2 2019
  • Figure 10: Number of Products by Stage and Molecule Types, H2 2019
Back to Top